Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection

Journal of Infectious Diseases

Volumn 184, Issue 10, 2001, Pages 1236-1245

  Colonno, R J ^a   Genovesi, E V ^a   Medina, I ^a   Lamb, L ^a   Durham, S K ^a   Huang, M L ^b   Corey, L ^b   Littlejohn, M ^c   Locarnini, S ^c   Tennant, B C ^d   Rose, B ^a   Clark, J M ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Victorian Infectious Disease Reference Laboratory   (Australia)

^d Department of Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; GUANOSINE; NUCLEOSIDE ANALOG; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXPERIMENTAL INFECTION; HEPATITIS VIRUS; LIFESPAN; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, VIRAL; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MARMOTA; TIME FACTORS; VIRUS REPLICATION;

EID: 0035890097     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/324003     Document Type: Article

References (41)

1. Overview on the epidemiology of hepatocellular carcinoma
2. Hepatitis B virus, the vaccine, and control of primary cancer of the liver
3. Hepatitis B viruses and cancerogenesis
4. Lamivudine as initial treatment for chronic hepatitis B in the United States
5. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
6. A one year trial of lamivudine for chronic hepatitis B
7. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
8. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
9. The woodchuck model of hepatitis B virus infection
10. Woodchuck hepatitis virus infection as a model for the development of antiviral therapies against HBV
11. The woodchuck: An animal model for hepatitis B virus infection in man
12. Chronic hepatitis and hepatocellular carcinoma associated with persistent woodchuck hepatitis virus infection
13. Influence of age on the response to experimental woodchuck hepatitis virus infection
14. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro
15. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
16. Potent efficacy observed with entecavir (BMS-200475) in duck model of hepatitis B virus replication
17. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
18. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
19. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
20. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection
21. Hepadna virus infection of peripheral blood lymphocytes in vivo: Woodchuck and chimpanzee models of viral hepatitis
22. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system
23. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples
24. Mucosal shedding of human herpesvirus 8 in men
25. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis
26. Antiviral activity of fialuridine in the woodchuck model of hepatitis B infection
27. The woodchuck model of hepatitis B virus infection
28. Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans
29. Hepadnaviridae and their replication
30. Hepatitis B: New approaches for antiviral chemotherapy
31. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells
32. In hepatocytes infected with duck hepatitis B virus, the template for RNA synthesis is amplified by an intracellular conversion pathway
33. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks
34. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by Adefovir in vitro do not lead to reduction of the closed circular DNA
35. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
36. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)
37. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus infection
38. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
39. Occult persistence and lymphotropism of hepadnaviral infection: Insights from the woodchuck viral hepatitis model